Acasti Pharma Inc  

(Public, CVE:APO)   Watch this stock  
Find more results for APO
-0.34 (-10.15%)
Nov 25 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 3.01 - 3.14
52 week 0.41 - 7.80
Open 3.10
Vol / Avg. 1,962.00/3,645.00
Mkt cap 32.09M
P/E     -
Div/yield     -
EPS -0.01
Shares 106.62M
Beta 1.22
Inst. own     -
Oct 14, 2015
Q2 2016 Acasti Pharma Inc Earnings Release

Key stats and ratios

Q3 (Aug '15) 2015
Net profit margin -17723.00% -611.46%
Operating margin -30857.86% -4580.02%
EBITD margin - -3717.11%
Return on average assets -14.60% -3.99%
Return on average equity -15.67% -4.98%
CDP Score - -


545 Prom du Centropolis Suite 100
+1-450-6864555 (Phone)
+1-450-6862505 (Fax)

Website links


Acasti Pharma Inc. is a Canada-based biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, in particular abnormalities in blood lipids, also known as dyslipidemia. The Company is engaged in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. CaPre, the Company's prescription drug candidate, is a purified omega-3 phospholipid concentrate derived from krill oil and is being developed to help prevent and treat hypertriglyceridemia. Onemia is a commercialized product of the Company marketed as a medical food. The Company is a subsidiary of Neptune Technologies and Bioressources Inc.

Officers and directors

Jerald J. Wenker Independent Chairman of the Board
Mario Paradis Chief Financial Officer
Pierre Lemieux Ph.D. Chief Operating Officer
Laurent Harvey Vice President- Clinical and Non-Clinical Affairs
Jean Daniel Belanger Secretary, Director- Corporate Affairs
Harlan W. Waksal M.D. Director
Age: 61
Valier Boivin Independent Director
Jean-Claude Debard Independent Director
Ronald Denis Independent Director
Pierre Fitzgibbon Independent Director
Age: 60